Abstracts tagged "Morphea"

Abstract Number: 1023 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-a (TNF-a) and Interferon Gamma Inducible Protein-10 (IP-10) As Predictors of Active Disease Status in Localized Scleroderma
Kathryn S. Torok¹, Jonathan Yabes², Qi Mi³, Christina Kelsey¹ and Kelsey Magee⁴, ¹Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, ⁴Pediatrics, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Localized scleroderma has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The extent and duration of…
Abstract Number: 3095 • 2015 ACR/ARHP Annual Meeting
Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study
Suzanne C. Li¹, Kathryn S. Torok², Sandy D. Hong³, Polly J. Ferguson⁴, C. Egla Rabinovich⁵, Mara L Becker⁶, Fatma Dedeoglu⁷, Maria F. Ibarra⁸, Robert C. Fuhlbrigge^9,10, Katie G. Stewart¹¹, Marilynn G. Punaro¹¹, Thomas Mason II¹², Elena Pope¹³, Ronald Laxer¹⁴, Gloria C. Higgins^15,16 and Brian Feldman¹⁷, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ⁴Dept of Pediatrics--Rheum, University of Iowa, Iowa City, IA, ⁵Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, ⁶Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁷Rheumatology, Boston Children's Hospital, Boston, MA, ⁸Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁹Program in Rheumatology, Division of Immunology, Boston Children’s Hospital, Boston, MA, ¹⁰Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Rheumatology, Mayo Clinic, Rochester, MN, ¹³Dermatology, Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Pediatric Rheumatology OSU, Nationwide Childrens Hosp, Columbus, OH, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hospital, Columbus, OH, ¹⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease that causes severe morbidity, including growth defects, cosmetic deformities, seizures and arthropathy.…
Abstract Number: 3149 • 2015 ACR/ARHP Annual Meeting
Predictors of Longitudinal Quality of Life Impact in Pediatric Localized Scleroderma
Kaveh Ardalan, Christina Kelsey and Kathryn S. Torok, Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease characterized by inflammation and fibrosis of the skin and a wide range of extracutaneous manifestations (ECMs). The…
Abstract Number: 1897 • 2014 ACR/ARHP Annual Meeting
Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski², Christina Kelsey³, Kelsey Magee⁴, Jonathan Yabes⁵, Abbe N. Vallejo⁶, Thomas A. Medsger Jr.⁷ and Carol A. Feghali-Bostwick⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA, ⁴Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissues which results in disfigurement and orthopedic complications, especially when the onset…
Abstract Number: 1324 • 2014 ACR/ARHP Annual Meeting
Predictors of Disease Relapse in Juvenile Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski² and Christina Kelsey³, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA
Background/Purpose Localized scleroderma (LS) is an autoimmune disease characterized by inflammation of the skin and underlying tissue leading tissue damage including atrophy, dyspigmentation, and fibrosis. …
Abstract Number: 1321 • 2014 ACR/ARHP Annual Meeting
A Pilot Study to Evaluate the Feasibility of Conducting Juvenile Localized Scleroderma Comparative Effectiveness Treatment Studies
Suzanne C. Li¹, Kathryn S. Torok², Mara L Becker^3,4, Fatma Dedeoglu⁵, Polly J. Ferguson⁶, Robert C. Fuhlbrigge^7,8, Gloria C. Higgins⁹, Sandy D. Hong¹⁰, Maria F. Ibarra¹¹, Ronald Laxer¹², Thomas G. Mason II¹³, Elena Pope¹⁴, Marilynn G. Punaro¹⁵, C. Egla Rabinovich¹⁶, Katie G. Stewart¹⁵ and Brian Feldman¹⁷, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁴Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁵Rheumatology, Boston Children's Hospital, Boston, MA, ⁶Dept of Pediatrics--Rheum, University of Iowa Carver College of Medicine, Iowa City, IA, ⁷Department of Dermatology, Brigham and Women's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA, ⁹Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁰Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ¹¹Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ¹²Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Mayo Clinic Rochester, Rochester, MN, ¹⁴Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁶Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, ¹⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose Juvenile localized scleroderma (jLS) often causes severe morbidity in the developing child, including growth defects and disfigurement. Optimal therapy is not known. The…
Abstract Number: 691 • 2013 ACR/ARHP Annual Meeting
Descriptive Review Of Morphea Subjects From a Single Cohort Center
Lesley Portugal¹, Muneera Naeem², Lakshmi N. Moorthy³ and Vivien M. Hsu⁴, ¹Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ, ²Medicine, Mountainside Hospital, Montclair, NJ, ³Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ, ⁴Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ
Descriptive review of Morphea subjects from a single cohort center Background/Purpose: Morphea, or localized scleroderma, is an idiopathic, rare fibrotic skin disorder that may result…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].